Tyagi joins Hikma with a brief to stimulate noninjectable R&D activity at a time when the company's generic drug unit is suffering.
The German company is seeking $22 million to support a clutch of clinical trials designed to expand use of Ameluz in types of skin cancer.
The impact of protracted contracting timelines can be felt throughout the study start-up process. Coupling predictive enrollment analytics with contract…
The setback leaves Concert committed to taking the drug forward in alopecia areata but uncertain of its future beyond the indication.
Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by…
A technology developed at the New York Genome Center that combines protein and messenger RNA expression measurements in cells has been licensed by BioLegend.
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
David Hung's decision to join Axovant after selling Medivation to Pfizer for $14 billion now looks more like a gamble that isn't paying off.
Nearly a year after closing a second funding round, cancer biotech BioClin has nabbed Esteban (Steve) Abella, M.D., as its new chief medical officer.